Optical Coherence Tomography (OCT) in Uveitis
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Dec 30, 2013
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of Optical Coherence Tomography (OCT), a special imaging technology, to better understand uveitis, which is inflammation of parts of the eye. The OCT machine takes detailed pictures of the eye's inner structures, helping doctors see the white blood cells and inflammation that occur in uveitis. Researchers hope that this technology will improve diagnosis and treatment for patients with various types of uveitis.
To participate in the trial, you need to be at least 18 years old and have specific signs of uveitis, such as certain levels of inflammatory cells in the eye or other related conditions like blood in the eye or retinal tears. If you decide to join, you can expect to undergo OCT imaging, which is a painless procedure that doesn’t involve any contact with your eye. It's important to note that participants must be able to give consent and keep their eyes steady during the imaging process. If you or a family member are dealing with uveitis, this trial could provide valuable information and potentially lead to better ways to manage the condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age and older
- * With one or more of the following clinical features:
- • 1. \>1+ AC cells;
- • 2. \>1+ vitreous haze;
- • 3. presence of vitreous cells;
- • 4. presence of blood in anterior chamber;
- • 5. presence of blood in vitreous;
- • 6. presence of aqueous or vitreous pigment.
- * In one of the following diagnostic categories as determined by a uveitis specialists:
- • 1. uveitis due to ankylosing spondylitis (positive HLA B27 genotype);
- • 2. uveitis due to sarcoidosis;
- • 3. uveitis of any additional type;
- • 4. uveitis masquerade such as pigment dispersion syndrome or Schaffer's sign;
- • 5. hyphema due to trauma or other causes;
- • 6. vitreous hemorrhage;
- • 7. retinal tear.
- Exclusion Criteria:
- • Inability to give informed consent;
- • Inability to maintain stable fixation for OCT imaging.
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
David Huang, MD, PhD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials